ABL Bio Inc

Capital Structure and Liquidity ABL Bio Inc maintains a strong liquidity position with KRW 111,981,944,910 in cash and equivalents, significantly exceeding its total liabilities of KRW 126,214,903,050. The company's current ratio of 1.43 indicates a moderate ability to meet short-term obligations. However, the company's free cash flow is negative at KRW -55,099,128,030, reflecting ongoing operational and capital expenditure demands. ### Profitability and Returns The company is currently unprofitable, with a net loss of KRW -37,806,499,280 and an operating loss of KRW -40,389,935,900. Return on equity (ROE) is negative at -24.44%, and return on assets (ROA) is also negative at -13.46%, indicating poor capital efficiency and asset utilization. These metrics are below the typical performance of the biotechnology industry, which often experiences high R&D costs and long development cycles before achieving profitability. ### Segments and Geographic Exposure The company's revenue is not disclosed by segment or geography in the available data, making it difficult to assess revenue concentration or geographic diversification. This lack of transparency may pose a risk to investors seeking to understand the company's exposure to specific markets or product lines. ### Growth Trajectory The company's growth trajectory is uncertain due to its current financial performance. Analysts have provided a mean price target of KRW 205,666.67 and a median price target of KRW 260,000.00, with a mean recommendation of 1.75 (leaning toward buy). However, the company's negative operating and net income suggest that near-term growth may be constrained by ongoing losses and high R&D expenditures. ### Risk Factors The company faces several risk factors, including its unprofitable status and negative cash flows. The risk assessment indicates low liquidity and dilution risk, with no immediate filing-based flags detected. However, the company's reliance on continued R&D investment and the uncertain regulatory environment for biopharmaceutical products could impact its long-term viability. ### Recent Events No specific recent events, such as filings or transcripts, are provided in the available data to indicate significant changes in the company's operations or strategy.